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Abstract
To eradicate measles in developing nations a vaccine capable of being administered at birth may be necessary. We immunized newborn
rhesus macaques with naked DNA encoding the measles virus hemagglutinin, fusion and nucleoprotein genes. Prior to vaccination we
passively transferred measles immunoglobulin to mimic maternal antibody. In the presence or absence of measles immunoglobulin, 23 of
25 infant macaques had detectable cell mediated immunity and 16 had protective levels of neutralizing antibody. The co-administration of
an IL-2/IgG plasmid augmented the vaccine, increasing cell mediated immunity in all infants and increasing the antibody response in infants
vaccinated without immunoglobulin. We show for the first time that DNA vaccination can protect a newborn primate from the high-level
viremia that correlates with severe measles, even in the presence of maternal antibody. Further, the addition of a molecular IL-2 adjuvant
augments this DNA vaccine.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Measles virus (MV), in the family Paramyxoviridae, is
the causative agent of measles (Griffin and Bellini, 1996).
Measles-related death in developing nations remains a lead-
ing cause of vaccine preventable mortality. Maternal anti-
bodies to MV prevent the live-attenuated vaccine from
being effective. To avoid the effects of maternal antibodies,
the measles vaccine is administered at 6–9 months of age in
developing countries and at 12–15 months in developed
nations. There remains a window of susceptibility to infec-
tion contributing to high measles morbidity and mortality,
from the time of maternal antibody decay below a protective
level and the time of vaccination. In countries where expo-
sure remains high, unvaccinated infants are susceptible to
measles, its complications, and immunosuppression, lead-
ing to opportunistic infections and approximately 800,000
deaths annually.
The MV envelope glycoproteins, hemagglutinin (H) and
fusion (F) proteins, are important in an anti-MV immune
response. Both H and F elicit neutralizing antibodies (NA)
and cell-mediated immunity (CMI), which is necessary for
protection from severe disease and death during MV infec-
tion (Burnet, 1968). Measles nucleoprotein (NP) is also
important because it contains human T-cell epitopes (Jaye et
al., 1998a; Jaye et al., 1998b) and immunity to NP can
protect infant rhesus macaques from pneumonitis following
intranasal challenge (Zhu et al., 1997).
Asian macaques model measles pathogenesis (Griffin
and Bellini, 1996; Hall et al., 1971; Kobune et al., 1996;
McChesney et al., 1997; Van Binnendijk et al., 1994) and
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these monkeys are the best model to study measles patho-
genesis and vaccine development (Osterhaus et al., 1994).
There are similarities between a rhesus measles model (Mc-
Chesney et al., 1997) and the clinical course of measles in
humans. Infected animals develop a maculopapular skin
rash beginning on the face and spreading to the chest and
abdomen lasting for 3–5 days. Additional signs include
depression, loss of appetite and shortness of breath with
coughing. All animals recover within 5–7 days but have
frequent episodes of bacterial gastroenteritis. Systemic in-
fection is quantified by viremia which peaks on day 7 and is
undetectable by day 28 post-inoculation (Zhu et al., 1997).
Rhesus macaques administered the currently used live-at-
tenuated measles vaccine do not have any of the above signs
and systemic infection is reduced to a very low or undetect-
able level (McChesney et al., 1997; Zhu et al., 1997).
DNA vaccines have shown promise in protecting exper-
imental animals from intracellular pathogens (Manickan et
al., 1997; Siegrist, 1997). DNA vaccination of newborn
rodents is effective in developing long-lived immune re-
sponses (Hassett et al., 2000), some in the presence of
maternal antibody (Hassett et al., 1997; Manickan et al.,
1997; Martinez et al., 1997; Van Drunen Littel-Van den
Hurk et al., 1999; Weeratna et al., 2001). DNA vaccination
of cotton rats to MV H and F proteins was effective al-
though not in the presence of maternal antibody (Schlereth
et al., 2000). Further, vaccination of juvenile macaques with
an MV DNA vaccine was protective against an MV chal-
lenge (Polack et al., 2000; Stittelaar et al., 2002). A DNA
vaccine expressing the three MV genes H, F, and NP may
circumvent the effect of maternal antibody, prime cellular
immunity in newborns, and protect them from disease.
Results
Experimental design and the administration of measles
immunoglobulin (MIG) to mimic the effects of maternal
antibody
We divided newborn monkeys (mean weight 0.5 kg) into
experimental groups that received 3.5 ml of MIG or PBS
(Fig. 1). It was verified that 3.5 ml of MIG mimics the levels
of naturally acquired maternal NA (Zhu et al., 2000) and
that MIG mimics the ability of maternal antibodies in in-
hibiting pox virus-vectored measles vaccines (Zhu et al.,
2000) and the live attenuated vaccine when administered at
birth (Katz et al., 2002). After subcutaneous inoculation in
the interscapular region, MIG equilibrates rapidly in the
extracellular fluid space and neutralizing titers are detect-
able in serum at 48 h (Tables 1 and 2). On the day of
vaccination, the geometric mean NA titers (GMT) in groups
3, 5, and 6 that received MIG was 264 (range 80 to 640;
Tables 1 and 2). In the DNA control group (group 1) on the
day of vaccination, 4 of 5 infants had natural maternal NA
with a GMT of 440 (Table 1) and their titers were not
significantly different from those infants that received MIG
(P  0.67).
Forty-eight h after MIG administration the infants were
vaccinated by the ID route with 100 g each of 3 plasmids
encoding MV H, F and NP genes. Group 1 infants were
Fig. 1. Experimental design: Vaccination of infant monkeys with DNA plasmids expressing MV H, F, and NP proteins in the presence or absence of MIG
and/or IL-2. Infants were vaccinated at birth, boosted at 8 weeks, and challenged at 20 weeks of age.
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vaccinated with 100 g each of 3 plasmids encoding
non-MV genes. At 48 h postvaccination, an optimal time
following DNA vaccination (Barouch et al., 1998), some
infants received 100 g of an IL-2/Ig plasmid or control
plasmid (Fig. 1). At 8 weeks the infant monkeys were
boosted with the same vaccines. At 5 months of age all
infants were challenged with MVDavis 87 by the IN route.
Cellular immunity to MV after vaccination
We measured CMI using an IFN- ELISPOT assay. No
pre-challenge IFN- secreting cells were detectable to MV
in infants vaccinated with control DNA with or without IL-2
(group 1, Fig. 2). On the day of boost 7 of 10 animals
administered IL-2 had CMI in the presence or absence of
MIG (Fig. 2). CMI peaked at 2 wk postboost. In the 15
animals not administered IL-2, 1 had detectable CMI on the
day of boost in the presence of MIG. Eight of 15 had CMI
2 wks postboost and 12 of 15 on the day of challenge.
Overall, 23 of 25 experimental infants had detectable CMI
with 18 of 25 positive on the day of challenge.
Humoral immune responses to MV after vaccination
Maternal antibodies in group 1 waned below protective
levels by week 20, the time of challenge (Table 1). In the
absence of MIG, 7 of 8 newborns had protective titers by
week 20 (groups 2 and 4, Tables 1 and 2). Four of 5 animals
in group 4 that received IL-2 had a postboost anemnestic
response (4-fold rise in titer) and 1 of 4 had a protective
titer after priming (Table 2). There was a statistically sig-
nificant difference between the NA titers of animals that
received IL-2 in the presence or absence of MIG (P  0.03,
Mann-Whitney test).
Infants vaccinated in the presence of NA had titers which
waned over time and 9 of 17 had protective titers on the day
of challenge (groups 3, 5, and 6; Tables 1 and 2). The titers
on the day of challenge were induced by the DNA vaccine
and not by MIG or maternal Ab (Katz et al., 2002; Zhu et
al., 2000) and control infants with maternal Ab in Group 1
had declines in titer to an unprotective level on the day of
challenge (Table 1). No newborns vaccinated in the presence
of MIG or maternal Ab had an anemnestic response to the
DNA boost with the exception of monkey 32501 (Table 1).
Effects of an IL-2/IgG plasmid administered 48 hours
after vaccination and boost
Clinically there were no signs of toxicity in infants ad-
ministered the IL-2/Ig plasmid. It was evident that the ad-
dition of the IL-2/Ig plasmid enhanced both NA and CMI,
although this enhancement was not significant (Mann-Whit-
ney test), probably due to a small sample size. However,
Table 1
Neutralizing antibody titers to MV in infant monkeys immunized with DNA in the presence or absence of MIG




MV DNA  PBS
Group 3
MV DNA  MIG or maternal antibody
32473 32489 32487 33177 33183 32396 32433 32490 32481 32488 32428 32430 32449 32495 32501
0a 320 640 640 40 160 10 10 10 160 80 320 640 80 640 160
8 80 320 40 40 80 80 20 10 20 80 80 40 20 320 40
10 40 80 80 40 160 640 40 20 20 160 40 40 20 320 160
20 10 40 10 40 10 80 160 10 80 320 80 10 160 80 20
22 640 640 2560 640 640 10240 20480 5120 10240 1280 640 1280 2560 640 640
a 0 is week of vaccination, 8 boost, 20 challenge, 22 is 2 weeks post challenge.
Table 2
Effect of an IL-2 molecular adjuvant on MV DNA vaccination
wk Reciprocal neutralizing antibody titer
Group 4
MV DNA  PBS  IL-2
Group 5
MV DNA  MIG  IL-2
Group 6
MV DNA  MIG  IL-2 control
33086 33085 33072 33140 33042 33090 33099 33102 33108 33118 33121 33143 33144 33161 33164
0a 10 10 10 10 10 80 160 160 160 160 640 80 160 640 160
8 10 20 20 80 10 40 10 20 640 10 40 40 160 160 80
10 160 640 80 640 160 40 40 10 160 40 10 80 160 320 160
20 320 320 320 320 80 160 40 80 80 40 40 320 20 40 40
22 640 640 2560 1280 2560 640 1280 640 640 1280 640 640 2560 1280 1280
a 0 is week of vaccination, 8 boost, 20 challenge, 22 is 2 weeks post challenge.
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there was a statistically significant difference between the
NA titers of animals that received IL-2 in the presence or
absence of MIG (P  0.03, Mann-Whitney test).
Viremia after MV-Davis challenge
All 5 DNA control monkeys, with or without maternal
antibody and the IL-2 adjuvant, had a peak of viremia on
day 7, then the viral load declined on day 14 and was
undetectable by day 28 (Group 1, Fig. 3A and D). The
viremia kinetics were similar to that of naı¨ve animals inoc-
ulated with MV (Zhu et al., 1997). It is important to note
that although the challenge stock lost 1 log10 of titer from
year 1 to year 2 of the study, control animals during both
years had similar 1 wk post-challenge viremia levels (Fig.
3D and Table 3). This loss of titer was coincident with an
absence of skin rash in any challenged monkeys in year 2;
however, group 3 animals (year 1) and group 6 animals
(year 2) had similar 1 and 2 wk post-challenge levels of
viremia and their geometric mean titers (GMT) were similar
irrespective of the loss of challenge stock titer (Fig. 3D).
Viremia peaked in groups 2, 3, and 6 at almost 1 log
lower than control monkeys on day 7 and was undetect-
able by day 14 (Fig. 3B); two animals in groups 3 and 6
had undetectable viremia throughout the study. Viremia
was undetectable in most monkeys in groups 4 and 5; 1
monkey had viremia 4 log10 lower than in controls on day
7 and it was undetectable by day 14 (Fig. 3C). Overall,
Fig. 2. MV-specific cell mediated immunity following DNA vaccination. PBMCs were stimulated overnight with live MV and IFN- spot forming cells were
counted by ELISPOT. MV-specific IFN- secreting responses in monkeys immunized with control DNA vaccine (group 1) or MV DNA vaccine without MIG
(group 2), with MIG or maternal Ab (group 3), without MIG and with IL-2 (group 4), with MIG and IL-2 (group 5), with MIG and the IL-2 control plasmid
(group 6): Black-hatched bars: day of boosting; open-hatched bars: 2 wk post boost; gray bars: day of challenge. *monkey # 33085, 2 wk post-boost 502
spots, day of challenge 144 spots; monkey # 33072, 2 wk post-boost 326 spots, day of challenge 50 spots.
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infants vaccinated with MV DNA in the presence or
absence of MIG had a statistically significant decrease in
1 wk post-challenge viremia compared to control animals
(Fig. 3D, P  0.0005, Druskal-Wallis Nonparametric
ANOVA).
Analysis of data (Table 3)
Animals with preexisting antibodies at the time of vac-
cination were as likely to develop detectable IFN- secret-
ing cells, though not NA as animals having no preexisting
antibodies (P  0.04, Fisher’s exact probability test). There
was no significant difference in peak viremia between ani-
mals with or without pre-existing antibody at the time of
vaccination. Post-challenge viremia was reduced in all MV
DNA-vaccinated groups as compared to controls and this
reduction was statistically significant in animals that re-
ceived IL-2 (P  0.01). After challenge, all animals had a
1 to 9-fold (average 4) rise in neutralizing antibodies (Ta-
bles 1 and 2) and four animals, #33142, #33144, #32433,
and #32501, had a CMI response 1 wk post challenge (data
not shown).
Discussion
The Infant can mount an effective immune response
following vaccination, though it is often skewed towards
Th2 (Barrios et al., 1996). To be effective against intracel-
lular pathogens, a Th1 response is required and it was
recently shown that human neonates vaccinated with Bacille
Calmette Gue`rin (BCG) are able to mount a Th1 response
with antigen-specific IFN- secretion (Marchant et al.,
1999). Neutralization of vaccine by maternal Ab is another
obstacle in many infant vaccine models including measles.
A recent study of human infants vaccinated with the live,
attenuated measles vaccine at 6, 9, and 12 mo of age showed
that vaccination at 6 mo, even in the absence of maternal
Ab, yielded only a 67% seroconversion rate as opposed to
vacciantion of 9 and 12 mo-old infants who had 100%
seroconversion rates (Gans et al., 1998). In contrast, an-
ti-MV CMI was found at similar levels in all 3 age groups.
These observations suggest that human infants may be more
competent to mount cellular immune responses than hu-
moral responses.
In the present study, newborn macaques were vaccinated
Fig. 3. Viremia following MV challenge. PBMC-associated viral load was measured by end-point dilution co-culture. (A) End-point titers of MV are shown
for monkeys that were immunized with control DNA (open symbols, group 1) or with control DNA and IL-2/IgG (closed symbols). (B) End-point titers are
shown for monkeys immunized with MV DNA without MIG (open symbols, group 2) and MV DNA without MIG  IL-2 (closed symbols, group 4). (C)
End-point titers are shown for monkeys immunized with MV DNA with MIG or maternal Ab (open symbols, group 3) and for monkeys immunized with
MV DNA with MIG  IL-2 (closed symbols, group 5). (D) Mean end-point titers for groups 1–6.
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with a novel MV DNA vaccine. NA with protective recip-
rocal titers ranging from 80 to 320 occured in 16 of 25 MV
DNA-vaccinated monkeys. With the addition of IL-2,
DNA-vaccination in the absence of MIG resulted in recip-
rocal NA titers (GMT 270, range 80–320) similar to juve-
nile monkeys administered the same vaccine without IL-2
(GMT 220, range 80–320, data not shown). This demon-
strates that infants can mount an effective humoral immune
response and this response is enhanced by a molecular IL-2
adjuvant to a level equivalent to that of a fully immuno-
competent host.
CMI was primed greatly by our MV DNA vaccine.
IFN- spot forming cells were detected in 92% of MV-
DNA vaccinated infants with or without the IL-2 adjuvant
or MIG. This inversely correlates with peak viremia after
challenge. The mean 1-wk post-challenge TCID50 was 511
in the absence of MIG and 631 in the presence of MIG;
control DNA-vaccinated animals had a mean TCID50 of
5942. There was no statistically significant difference in
peak viremia between animals with or without pre-chal-
lenge NA (P  0.07). However, peak viremia in animals
with pre-challenge CMI was significantly lower than in
animals without CMI (P  0.02). This suggests that the
CMI induced by the MV DNA vaccine is more effective in
protecting infant macaques from high-level viremia than is
NA. It is important to note that although addition of an IL-2
molecular adjuvant to the MV DNA did not enhance NA
titers in the presence of MIG, it was effective in increasing
CMI in the presence of MIG, with many infants mounting
responses following initial vaccination (detectable on the
day of boost, Fig. 2).
A Th1 response to a DNA vaccine can be enhanced by
the addition of an IL-2 molecular adjuvant (Barouch et al.,
2000; Chow et al., 1997; Kim et al., 1999; Kim et al., 2001).
Macaques immunized with an HIV/SIV DNA vaccine and
IL-2 had significant enhancement of anti-HIV antibodies
and stronger CTL responses (Kim et al., 2001). In the
present study, the addition of an IL-2 molecular adjuvant
enhances both cellular and humoral immunity, although not
with statistical significance. Interestingly, animals vacci-
nated with this MV DNA vaccine in the presence of IL-2
(groups 4 and 5) had very low or undetectable viremia
Table 3
Immune responses to MV DNA vaccination and viral load after challenge
Group Vaccine variables Monkey # Neutralizing antibodya IFN- elispotb MV viral loadc
1 control DNA 32473   
32489   
32487   
33177   
33183   
2 MV DNA/PBS 32396   
32433   
32490   
3 MV DNA/MIG or maternal Ab 32481   
32488   
32428   
32430   
32449   
32495   
32501   
4 MV DNA/PBS & IL-2 33086   
33085   
33072   
33140   
33142   
5 MV DNA/MIG & IL-2 33090   
33099   
33102   
33108   
33118   
6 MV DNA/MIG & IL-2 control 33121   
33143   
33144   
33161   
33164   
a ()  40 reciprocal titer, ()  40 and 160, () 160 and  640, ()  640.
b samples were collected on the day of boost, 2 weeks post-boost and on the day of challenge. () positive at 1 time point, () positive at 2 time points,
() positive at all 3 time points.
c () not detected, () 103 TCID50/106 PBMC on day 7, ()  10 TCID50/106 PBMC on day 14 and ()  103 TCID50/106 PBMC on day 7
and  10 TCID50/106 PBMC on day 14.
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similar to juveniles vaccinated and boosted with the
Moraten vaccine strain in a previous study (Zhu et al.,
1997). The reduction of viral loads in groups 4 and 5 was
not due to nonspecific effects of IL-2 nor to the loss of MV
challenge stock titer since monkeys that received control
plasmid DNA with the IL-2/IG plasmid had high viral loads
(Fig. 3A, Table 3). This suggests that IL-2 may promote an
immune response with an increased affinity or avidity to
MV antigens; this has not yet been examined.
Several DNA vaccines tested in animal models, includ-
ing infants, have been shown to be safe. It would be prac-
tical to use DNA vaccination at birth as a means of protect-
ing infants from an immunosuppressive systemic infection
such as measles. With the addition of an IL-2 molecular
adjuvant, the immune response was enhanced and in 70% of
the infants CMI was induced after a single immunization
(Fig. 2). An alternative Th1 promoting adjuvant would be
BCG, as BCG administered at birth produces a memory Th1
response similar in magnitude to that in adults (Marchant et
al., 1999).
The MV vaccines in use today are effective when ad-
ministered at 6–9 mo of age and they prime a Th1 T cell
response (Gans et al., 2001). That a DNA vaccine is effec-
tive in the presence of anti-viral antibody in a newborn
primate model is a novel observation. The addition of an
IL-2 molecular adjuvant augments protective immunity in
this model; this requires further study. Optimizing this MV
DNA vaccine so that it may be administered in a single
injection at prime and boost, testing the duration of immu-
nity through the first year of life, and determining that this
novel vaccine strategy does not interfere with replication of
the live attenuated vaccine administered at 6–9 mo of age in
developing countries are current goals.
Materials and methods
The expression vector pND
The plasmid pND was used for expression of vaccine
genes. It contains the human CMV IE1 promoter-enhancer
region (Chapman et al., 1991), the IE1 intron, and the
bovine growth hormone polyadenylation signal in a pUC19
backbone. The polyadenylation signal was amplified from
the commercial expression vector, pcDNA3 (Invitrogen),
with the primers PM10: GCGTGCAGCA TATGTTCCGC
CTCAGAAGCC ATAG and PM11:CACTGCTTAC TG-
GCTTATCG. The amplified product is 456 bp and contains
the polyadenylation region and part of the polylinker se-
quence. This was digested with EcoRI and NdeI and the 334
bp fragment was inserted into pUC19 which had been di-
gested with the same enzymes producing plasmid
pUC19BGA. The CMV IE1 enhancer, promoter and intron
region was amplified from the Towne strain with the prim-
ers PM5: GCTGTGCGCA GGCGGAGTGA ATTATTG-
GCT and PM2: GCATGGTACC TCTGGAATCC TCT-
AGCGCTGG. The 1997 bp product was digested with FspI
and SalI and inserted into pUC19BGA which had been
digested with PvuII and KpnI to create pCMVBGH. The final
expression vector, pND, was then created by enhancing the
linker portion of the vector by inserting the linker.2 sequence:
CCGTCGACAGAT CTGGCGCCGC TAGCATCGAT
CCCGGGGGAT CCAGAGGTAC CGAGCTCGAA
TTCGG between the SalI and EcoR of pCMVBGH.
Vaccine plasmids
Measles genes from the Edmonston vaccine strain were
cloned and inserted into the Bluescript II SK cloning vector
(Rota et al., 1994) and then digested with compatible re-
striction enzymes and inserted into pND. Plasmids were
verified by restriction mapping and sequencing across junc-
tions. Expression of antigen was confirmed for each plasmid
after transfection of BHK cells and analysis by western
blotting using sera from MV-infected monkeys. Control
plasmids used for immunization consisted of the pND vec-
tor containing genes from influenza H and influenza NP
(strain A/PR/8/32, kindly provided by P. Palase) and E. coli
-galactosidase. The IL-2/IgG plasmid has been previously
described (Barouch et al., 2000). This vector expresses a
fusion protein consisting of human IL-2 and the Fc portion
of the human IgG heavy chain. The control for the IL-2/IgG
plasmid was the empty vector VCL1012. Endotoxin was
measured by the Limulus assay and was less than 3 U/g
DNA.
Passive transfer of MIG prior to vaccination
MIG is a pool of heated-inactivated sera from monkeys
that contracted measles during an outbreak among unvac-
cinated juvenile monkeys at the California National Primate
Research Center in 1995 (Zhu et al., 2000). The reciprocal
NA titer of MIG is 5120 by 50% end-point titration. MIG,
3.5ml, was administered to infant rhesus monkeys by sub-
cutaneous inoculation 48 h prior to vaccination. Infant con-
trols were inoculated with 3.5 ml PBS which mimics mea-
sles sero-negative immunoglobulin (Zhu et al., 2000).
Vaccination with MV DNA
The infant study occurred over a 2 year period, the first
year involving monkeys beginning with the number 32, and
in the second year monkeys beginning with the number 33.
Colony-bred male and female newborn rhesus macaques
were housed in accordance with the guidelines of the Com-
mittee on Care and Use of Laboratory Animals, National
Resources Council. Infant monkeys (2–4 d old, mean body
weight 0.5 kg) were assayed for maternal antibody by IgG
ELISA (Hummel et al., 1992) and vaccinated with either
MV DNA or control DNA plasmids (Fig. 1). Each plasmid
was diluted to 50 g/100 l in .15 M NaCl. Animals were
inoculated intradermally (ID) at 2 sites per plasmid in the
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interscapular region. Forty-eight h after vaccination, 10 MV
DNA-vaccinated animals and 2 control DNA-vaccinated
animals were administered an IL-2/IgG plasmid ID, 100 g
in a single dose. Five animals received a plasmid control for
the IL-2/IgG. All animals were boosted with the same reg-
imen/ IL-2/IgG at 8 wk after vaccination. The route and
dose of DNA had been optimized in earlier studies (unpub-
lished data).
Challenge with pathogenic MV
At 20 wk of age, the monkeys were challenged by intra-
nasal (IN) inoculation of a standard dose of the Davis 87
isolate of MV grown in rhesus peripheral blood mononu-
clear cells (PBMC) (McChesney et al., 1997). In the second
year, the challenge stock had lost 1 log10 of titer from
unknown causes. The animals were monitored daily for
anorexia, depression, coughing, diarrhea and skin rash.
They were bled on days 7, 14, and 28 postchallenge. Viral
loads were quantified in PBMC by end-point dilution co-
culture with Raji cells (Zhu et al., 1997).
Measurement of MV anti-NP IgG and neutralizing
antibody
MV antibodies were measured in serum samples prior to
initial vaccination by an NP-specific IgG ELISA (Hummel
et al., 1992). Neutralizing antibodies were measured by viral
antigen reduction in Vero cells in 96-well plates (Zhu et al.,
1997). The serum neutralizing titer is reported as the highest
dilution showing a 50% reduction in viral antigen.
IFN- ELISPOT assay
PBMC were isolated from heparinized blood and cryo-
preserved in liquid nitrogen. PBMC were re-suspended at 1
 106 cells/100l in AIM V medium supplemented with
10% FCS. Cells were incubated in a 48-well plate and
stimulated overnight with live MV, Edmonston strain
(American Type Culture Collection), or positive control
stimulation with 10 ng/ml PMA and 1 g/ml ionomycin or
negative medium control. Following overnight incubation,
cells were plated in a 96-well ELISPOT plate coated with
antibody to rhesus IFN- at 5  105 cells/well for medium
control and MV-stimulated wells and at 1  104 cells/well
for PMA/ionomycin wells. Spots per well were counted and
averaged. ELISPOT plates were prepared according to kit
instructions (U-Cytech BV, Utrecht, The Netherlands). A
positive result was at least 10 spots per well and  mean 
2 SD of the medium control. The mean number of spots in
medium control wells was subtracted from the mean of
experimental wells and the resulting number of spots ad-
justed to 106 PBMC.
Statistical analysis
IFN- secreting cells, NA titer and viremia were consid-
ered dichotomous variables. Fisher’s exact probability test
was used to analyze the relationship between antibody sta-
tus or pre-challenge CMI, with or without NA, at the time of
challenge and viremia. Differences in post-challenge peak
virus load among animals with or without NA at the time of
vaccination were analyzed using the Kruskal-Wallis one-
way ANOVA by ranks. Post-hoc testing was performed
using Dunne’s multiple comparisons test. To analyze the
effects of IL-2 the Mann-Whitney U test was performed.
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